Vanderbilt-Ingram Cancer Center | Strategic Alliance Partners

June 08, 2023

Dr Holowatyj discusses symptoms associated with appendix cancer, challenges related to understanding the incidence and risk factors of this disease, and ongoing research regarding potential genetic links to this rare cancer.

June 07, 2023

Brian I. Rini, MD, FASCO, discusses long-term survival outcomes in patients with advanced clear cell renal cell carcinoma who received frontline pembrolizumab and axitinib in the phase 3 KEYNOTE-426 trial.

June 02, 2023

Michael K. Gibson MD, PhD, discusses the importance of addressing unmet needs related to treatment for patients with gastrointestinal cancers.

May 26, 2023

Dana B Cardin, MD, MSCI, discusses the importance of identifying comorbidities and high-risk features when determining the optimal treatment approach for patients with pancreatic cancer.

May 24, 2023

Gastrointestinal oncology experts discuss current strategies and novel developments in gastrointestinal cancers, the role of intestinal dysbiosis and gastrointestinal carcinogenesis, germline genetic features in appendiceal cancer, and the need for anticipatory, multidisciplinary guidance in clinical practice.

May 22, 2023

Dana B Cardin, MD, MSCI, discusses the rationale for exploring KRAS as a therapeutic target in pancreatic cancer.

May 22, 2023

Brian C. Grieb, MD, PhD, emphasizes the importance of investigating agents that target the MYC oncogene, as well as supportive cofactors, in colorectal cancer and other tumor types.

May 19, 2023

Brian I. Rini, MD, FASCO, discusses efforts to utilize genetic testing to improve treatment selection in renal cell carcinoma through the phase 2 OPTIC RCC trial.

May 18, 2023

Brian C. Grieb, MD, PhD, discusses historical barriers to targeting the MYC oncogene in patients with colorectal cancer and the rationale for an ongoing phase 1/2 clinical trial that may demonstrate an effective way to target MYC in CRC and other solid tumors. 

May 16, 2023

Laura Goff, MD, discusses the investigation of adjuvant atezolizumab plus bevacizumab in hepatocellular carcinoma.

May 16, 2023

Mariana X. Byndloss, DVM, PhD, discusses the relationship between the gut microbiome and the risk of developing cancers such as colorectal cancer.

May 15, 2023

Michael K. Gibson MD, PhD, discusses advancements in the identification of key biomarkers for patients with gastric or gastroesophageal junction adenocarcinoma, and the subsequent development of biomarker-driven therapeutics in this disease space.

May 12, 2023

Laura Goff, MD, discusses the key takeaways from results of the phase 3 SWOG 1815 trial in newly diagnosed patients with advanced biliary tract cancers.

May 11, 2023

Michael K. Gibson MD, PhD, discusses current and emerging biomarkers in the treatment of patients with gastric or gastroesophageal junction adenocarcinoma.

May 08, 2023

Andreana N. Holowatyj, PhD, MSCI, discusses results from an investigation of germline genetic features that may confer cancer susceptibility in patients with appendiceal cancer.

May 05, 2023

Fielding questions from the audience, expert oncologists discuss clinical trials, molecular testing, and early-stage disease in the context of HER2-amplified colorectal cancer.

April 28, 2023

Looking toward the future management of HER2-amplified colorectal cancer, panelists reflect on ongoing clinical trials and evolving treatment strategies.

April 28, 2023

Expert perspectives on the real-world use of HER2-directed therapies in patients with HER2-amplified colorectal cancer.

April 21, 2023

A focused discussion on HER2-amplified colorectal cancer and respective clinical trials that inform use of targeted agents in this setting.

April 21, 2023

Broadening their conversation, expert oncologists define the treatment algorithm for patients diagnosed with colorectal cancer.